by Major Pharmaceuticals · 1 BOTTLE, PLASTIC in 1 CARTON / 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
This is a package of 100 tablets of Aprodine Pseudoephedrine HCl, Triprolidine HCl 60 mg; 2.5 mg Tablet, Film Coated from Major Pharmaceuticals, marketed since Nov 2022 and currently FDA-listed; retail pharmacies pay about $0.0741 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.
NDC 00904-7302-60
🏷️ FDA NDC (as labeled)0904-7302-60billing pads the labeler segment with a zero
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
GPI-1443993002800330
GCN Seq No001151
GCN96445
HICL code000505
Ingredient (HICL)Triprolidine/Pseudoephedrine
HIC1 codeZ
Therapeutic class — broad (HIC1)Body As A Whole
HIC2 codeZ2
Therapeutic class — intermediate (HIC2)Antihistamines, Antiserotonins, Immunosuppressants
HIC3 codeZ2N
Therapeutic class — specific (HIC3)1St Gen Antihistamine And Decongestant Combination
AHFS code04:04.20.00
AHFS classPropylamine Derivatives
FDB label nameAPRODINE TABLET
FDB brand nameAprodine
Legend statusO — Over-the-counter (OTC) drug or device
Quick answers
GSN (GCN sequence number):001151
GCN:96445
GPI-14 (Medi-Span):43993002800330
HICL (First Databank):000505
AHFS class code:04:04.20.00
RxCUI (RxNorm):1099446
Why two NDCs?
The FDA registers this code as 0904-7302-60 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00904-7302-60. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
This medicine belongs to the Other antihistamines for systemic use class.
Drug family (ATC)Other antihistamines for systemic use
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
Label name APRODINE TABLETIngredient Triprolidine/Pseudoephedrine
🧪 What is this product?
Aprodine is an over-the-counter film-coated tablet taken by mouth that combines two active ingredients commonly used to ease cold and allergy symptoms. Pseudoephedrine is a decongestant typically used to relieve nasal and sinus congestion, while triprolidine is an antihistamine that functions to reduce sneezing, runny nose, and itching. This product is marketed as an OTC monograph drug, meaning it follows FDA's established rules for this category of combination cold and allergy relief products.
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
Price system
Per ea
Per package
Retail pharmacies payNADAC · weekly
$0.074
$7.41 / 100 tablets
Medicaid paysCMS SDUD · 12 mo
$0.2891
$28.91 / 100 tablets
Medicare drug plans payPart D · quarterly
No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
▲ Up 64% over the last 13 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
1 BLISTER PACK in 1 CARTON / 24 TABLET, FILM COATED in 1 BLISTER PACK
$0.0741 / ea
$1.78
2022-11-11
—
Active
00904-7302-60 You're viewing thisMain listing
1 BOTTLE, PLASTIC in 1 CARTON / 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
$0.0741 / ea
$7.41
2022-11-11
—
Active
Swipe sideways for more columns →
This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.0741 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 58% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
This is a 100-count package — 1 bottle, plastic in 1 carton / 100 tablet, film coated in 1 bottle, plastic.
How does this package differ from NDC 00904-7302-24?
Both are Aprodine Pseudoephedrine HCl, Triprolidine HCl 60 mg; 2.5 mg Tablet, Film Coated — the drug itself is identical. This page's package is the 100-count one, while NDC 00904-7302-24 is the 24 tablets package.
What NDC number is used to bill for this package of Aprodine Pseudoephedrine HCl, Triprolidine HCl 60 mg; 2.5 mg Tablet, Film Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.
Inactive ingredients, also called excipients, are components of the drug product
other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors,
or other formulation ingredients.
Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
Uses temporarily relieves these symptoms due to hay fever (allergic rhinitis) or other upper respiratory allergies: runny nose itchy, watery eyes nasal congestion sneezing itching of the nose or throat temporarily relieves these symptoms due to the common cold: runny nose sneezing nasal congestion
⏱️Dosage and Administration39 words▾
Directions do not take more than directed adults and children 12 years and over: take 1 tablet every 4 to 6 hours. Do not take more than 4 tablets in 24 hours. children under 12 years: do not use
⚠️Warnings198 words▾
Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product. Ask a doctor before use if you have high blood pressure heart disease thyroid disease diabetes glaucoma a breathing problem such as emphysema or chronic bronchitis difficulty in urination due to enlargement of the prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers.
When using this product do not exceed recommended dosage excitability may occur, especially in children use caution when driving a motor vehicle or operating machinery drowsiness may occur avoid alcoholic beverages alcohol, sedatives, and tranquilizers may increase drowsiness Stop use and ask a doctor if nervousness, dizziness, or sleeplessness occur symptoms do not improve within 7 days or occur with fever If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
📦Storage and Handling36 words▾
Other information TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BLISTER IS TORN OR BROKEN store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F) see end flap for expiration date and lot number
🧪Active Ingredient13 words▾
Active ingredients (in each tablet) Pseudoephedrine HCl 60 mg Triprolidine HCl 2.5 mg
Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.
📄Ask a Doctor Before Use If36 words▾
Ask a doctor before use if you have high blood pressure heart disease thyroid disease diabetes glaucoma a breathing problem such as emphysema or chronic bronchitis difficulty in urination due to enlargement of the prostate gland
📄Ask a Doctor or Pharmacist Before Use If14 words▾
Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers.
📄When Using This Product38 words▾
When using this product do not exceed recommended dosage excitability may occur, especially in children use caution when driving a motor vehicle or operating machinery drowsiness may occur avoid alcoholic beverages alcohol, sedatives, and tranquilizers may increase drowsiness
📄Stop Use and Ask a Doctor If23 words▾
Stop use and ask a doctor if nervousness, dizziness, or sleeplessness occur symptoms do not improve within 7 days or occur with fever
🤰If Pregnant or Breast-Feeding10 words▾
If pregnant or breast-feeding, ask a health professional before use.
📄Keep Out of Reach of Children21 words▾
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
📄Questions or Comments4 words▾
Questions or comments? 1-800-426-9391
📄Package Label / Principal Display Panel64 words▾
Principal display panel MAJOR ® NDC 0904-7302-60 maximum strength Aprodine™ tablets pseudoephedrine HCl 60 mg nasal decongestant triprolidine HCl 2.5 mg antihistamine FOR PHARMACY USE ONLY. NOT FOR RETAIL SALE. relieves: • nasal congestion • sneezing • runny nose • itchy, watery eyes actual size 100 tablets 50844 REV1123A28712 Distributed by: MAJOR ® PHARMACEUTICALS Indianapolis, IN 46268 (800) 616-2471 www.major-rugby.com Major 44-287A Major 44-287A
No label section mentions that — try another word, or open the full label on DailyMed below.
Glossary — plain-language definitions of medical terms used in this label:
depression: A lasting low mood with loss of interest that affects everyday life.
glaucoma: An eye condition, often linked to high pressure inside the eye, that can slowly damage vision.
inhibitor: A substance that blocks an enzyme or transporter, which can raise the levels of drugs it normally handles.
NDC: A unique number that identifies a specific medicine, its maker, strength, and package size.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
9.3K
Units reimbursed last 4 qtrs
428.5K
Gross reimbursed last 4 qtrs
$123.9K
Avg / prescription
$13.31
Avg / unit
$0.2891
Latest quarter Q1 2026
2.4KRx
Medicaid pays / ea
$0.2891
gross reimbursed
vs
NADAC / ea
$0.0741
acquisition cost
=
Spread
+$0.2150
+290% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
96% FFS
Fee-for-service · 8,964 Rx Managed care · 345 Rx
State Medicaid map
Units reimbursed · per 100k residents
3.41,060
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
1California1,060 /100k
2Mississippi471 /100k
3New Jersey10.4 /100k
4New York3.4 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
Medicaid utilization by pack size
Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
Drug total (last 4 qtrs): 16,159 Rx · 646,090 units · $209,546 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Aprodine (this brand).
Top reported reactions
Renal Failure5
Chronic Kidney Disease4
Pneumonia4
Death3
Diarrhoea3
End Stage Renal Disease3
Fatigue3
Age at onset
Adult5
Elderly1
Reporter sex
Male · 48%
Female · 52%
Serious outcomes
Death9
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.
